66 completed, 14 terminated, 4 unknown, 3 recruiting. 53 Phase 1, 30 Phase 2, 4 Not applicable, 2 Phase 3, 1 Early Phase 1.
Follow Familial ependymoma: new trials by email Literature Review of Familial ependymoma trials Research Report on Familial ependymoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling Functional Precision Medicine - Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Florida International University | 65 | 2023-02-22 | 2026-08-26 |
| Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents Ependymoma of Brain, Pediatric Solid Tumor | Recruiting | Institut Claudius Regaud | 370 | 2021-09-30 | 2026-06-04 | |
| Ex Vivo Drug Sensitivity Testing and Mutation Profiling Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia | Completed | Florida International University | 25 | 2019-02-21 | 2023-05-10 | |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-06-05 | 2026-10-16 |
| Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors Everolimus, Laboratory Biomarker Analysis, Pharmacological Study - CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 22 | 2018-01-13 | 2021-08-27 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors Intra thecal methotrexate, topotecan, cyclophosphamide - Recurrent Childhood Medulloblastoma, Recurrent Childhood Ependymoma | Phase 2 | Terminated | Nicklaus Children's Hospital f/k/a Miami Children's Hospital | 3 | 2016-02-01 | 2020-01-10 |
| Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging - Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 71 | 2015-06-03 | 2026-07-20 |
| An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma 16 weeks of VEC + CDDP, VEC + HD-MTX, Chemotherapy + Valproate - Childhood Ependymoma | Phase 2 / Phase 3 | Recruiting | Centre Leon Berard | 536 | 2015-06-02 | 2024-04-26 |
| Everolimus for Children With Recurrent or Progressive Ependymoma Everolimus - Recurrent Childhood Ependymoma | Phase 2 | Completed | University of Texas Southwestern Medical Center | 11 | 2015-02-01 | 2024-05-08 |
| Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors gallium Ga 68-edotreotide, positron emission tomography, computed tomography - Acoustic Schwannoma, Adult Anaplastic Astrocytoma | Not applicable | Withdrawn | Sue O'Dorisio | 2013-09-01 | 2017-04-28 | |
| Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Sunitinib Malate - Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2012-01-01 | 2015-08-27 |
| Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 Erlotinib - Ependymoma | Phase 2 | Terminated | OSI Pharmaceuticals | 4 | 2011-05-23 | 2024-12-06 |
| PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors VEGF inhibitor PTC299 - Brain and Central Nervous System Tumors | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 28 | 2010-11-01 | 2015-05-04 |
| Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma erlotinib, etoposide - Recurrent or Refractory Pediatric Ependymoma | Phase 2 | Terminated | OSI Pharmaceuticals | 25 | 2010-09-27 | 2024-12-12 |
| Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer cyproheptadine hydrochloride, placebo - Cancer | Phase 3 | Terminated | University of South Florida | 22 | 2010-06-01 | 2015-07-02 |
| Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma Carboplatin - Ependymoma | Phase 2 | Terminated | Ann & Robert H Lurie Children's Hospital of Chicago | 75 | 2010-04-01 | 2015-03-02 |
| Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 129 | 2010-03-01 | 2014-11-05 |
| Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors vorinostat, temozolomide, diagnostic laboratory biomarker analysis - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2010-02-01 | 2013-05-03 |
Showing 20 of 92. Sign in to see all of them.
Medulloblastoma (74) · Astrocytoma (70) · Central Nervous System Neoplasms (57) · Optic Nerve Glioma (55) · Oligodendroglioma (51) · Choroid Plexus Neoplasms (44) · Neuroblastoma (29) · Sarcoma (26) · Rhabdoid Tumor (25) · Neuroectodermal Tumors, Primitive, Peripheral (24) · Ependymoma (22) · Osteosarcoma (20) · Glioma (18) · Brain Neoplasms (17)
Neoplasms by Histologic Type (88) · Neoplasms (86) · Neoplasms, Germ Cell and Embryonal (85) · Neoplasms, Glandular and Epithelial (85) · Neoplasms, Nerve Tissue (85) · Neuroectodermal Tumors (85) · Neoplasms, Neuroepithelial (81) · Neoplasms by Site (80) · Nervous System Diseases (79) · Nervous System Neoplasms (79) · Neuroectodermal Tumors, Primitive (68) · Glioma (67) · Central Nervous System Diseases (60) · Brain Diseases (56) · Cranial Nerve Diseases (55)
Filgrastim (13) · Carboplatin (9) · Temozolomide (9) · Cyclophosphamide (6) · Etoposide (6) · Peripheral Blood Stem Cell Transplantation (6) · Erlotinib Hydrochloride (4) · Irinotecan (4) · Magnetic Resonance Spectroscopy (4) · sargramostim (4) · Busulfan (3) · Cisplatin (3) · Granulocyte Colony-Stimulating Factor (3) · O(6)-benzylguanine (3) · Oxaliplatin (3)
National Cancer Institute (NCI) (27) · Pediatric Brain Tumor Consortium (11) · Children's Oncology Group (8) · Children's Cancer and Leukaemia Group (4) · Duke University (4) · National Institutes of Health Clinical Center (CC) (3) · City of Hope Medical Center (2) · Florida International University (2) · Memorial Sloan Kettering Cancer Center (2) · OSI Pharmaceuticals (2) · University of South Florida (2) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Assistance Publique Hopitaux De Marseille (1) · Barbara Ann Karmanos Cancer Institute (1) · Centre Leon Berard (1)
United States (81) · Canada (17) · Puerto Rico (9) · Australia (8) · United Kingdom (7) · Switzerland (6) · Ireland (4) · Netherlands (4) · New Zealand (4) · France (3) · Austria (1) · Belgium (1) · Czechia (1) · Denmark (1) · Germany (1)
Elizabeth Fox, MD (3) · Darell D. Bigner, MD, PhD (2) · James Croop, MD, PhD (2) · Katherine Warren, MD (2) · Kim Kramer, MD (2) · M. Sue O'Dorisio, MD, PhD (2) · Mark W. Kieran, MD, PhD (2) · Maryam Fouladi (2) · Maryam Fouladi, MD (2) · Roger J. Packer, MD (2) · Susan M. Blaney, MD (2) · AeRang Kim, MD (1) · Alice Lee (1) · Allen R. Chen, MD, PhD, MHS (1)
PMID 31401903, PMID 16234526, PMID 16408203, PMID 16532433, PMID 16533779, PMID 16914576, PMID 17019740, PMID 17610262, PMID 17634493, PMID 17941066, PMID 18048828, PMID 18281544, PMID 18281546, PMID 18447671, PMID 18989154, PMID 19065567, PMID 19075272, PMID 19430790, PMID 19533657, PMID 20044751, PMID 20049936, PMID 20460632, PMID 20847174, PMID 21115653, PMID 23554030, PMID 27109549, PMID 32623479, PMID 33852135, PMID 34738048, PMID 35591977, PMID 35720069, PMID 36950217, PMID 38605166, PMID 38815151, PMID 39298716, PMID 9849694
U01CA081457 (11), U01CA097452 (8), U10CA098543 (4), U10CA180886 (3), UM1CA081457 (3), U10CA081920 (2), 2009 (1), P30CA006516 (1), P30CA012197 (1), P30CA016087 (1), P30CA022453 (1), P30CA033572 (1), P30CA086862 (1), U54MD012393 (1), UG1CA189958 (1)